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sHerein we report major new findings published between
June 2011 and May 2012 in patients with non–ST-segment
elevation acute coronary syndromes (NSTE-ACS).
Background
Acute coronary syndromes (ACS) were responsible for
approximately 1.2 million discharges in the United States in
2009, of which approximately 30% were due to unstable
angina (UA) and 70% to myocardial infarction (MI) (1).
The proportion of ST-segment elevation myocardial infarc-
tion (STEMI) relative to non–ST-segment elevation myo-
cardial infarction (NSTEMI) continues to decrease, with
the former now constituting less than one third of the
myocardial infarctions (MIs) in the United States (1).
Therefore, NSTE-ACS accounts for more than two thirds
of all cases of ACS; NSTE-ACS, in turn, includes patients
with NSTEMI and UA. With more sensitive cardiac-
specific troponin analyses (see the following), an increasing
fraction of patients formerly considered to have UA now
turn out to have some detectable myocardial necrosis. As
these more sensitive tests are used more widely, it is likely
that the incidence of UA will continue to decrease and
indeed may virtually disappear as a discrete entity. For all
practical purposes, NSTE-ACS will be equivalent to
NSTEMI.
Although the overall incidence of first MI in the United
States has declined over the past 2 decades in both men
(2% per year) and women (1% per year) (2), and the rate
of all death attributable to cardiovascular diseases overall
continues to decrease slowly in developed nations (3), these
trends are not necessarily consistent across age, sex, and
geographic subgroups. For example, the incidence rates of
ACS in middle-aged women in Western Australia have
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accepted August 13, 2012.increased during the past decade, a finding that may be
explained by higher rates of obesity and diabetes (4).
urthermore, despite the overall improvement in the care of
atients with cardiovascular disease, including NSTE-ACS,
ardiovascular death remains the leading cause of mortality
orldwide, with coronary heart disease (CHD) responsible
or 1 in 6 deaths in the United States and 1 American
xperiencing a coronary event every 25 s (1).
isk Factors
everal new investigations of novel risk factors beyond those
dentified in the original Framingham cohort were pub-
ished during the past year. Among these, diminishing
ardiorespiratory fitness (as assessed by serial exercise tread-
ill testing) (5), patients with human immunodeficiency
irus who were treated with protease inhibitors (compared
ith no protease inhibitors) (6), and those with low levels of
5-hydroxyvitamin D (other than those with an elevated
arathyroid hormone level) (7) represent subgroups at es-
ecially high risk of ACS and cardiovascular mortality.
hese observational associations should be considered hy-
othesis generating because confounding factors may ex-
lain some or all of the observed relationships.
Other analyses illustrate the broad range of factors that
an trigger ACS including viruses such as human papillo-
avirus (8), a sexually transmitted virus that causes ano-
enital cancer; the herbal stimulant khat (9), which can
nduce coronary spasm similar to that caused by amphet-
mines; psychological stress in spousal caregivers of cancer
atients (10); and periodic limb movements during sleep
11), which may represent an endophenotype for restless leg
yndrome given their clinical overlap and shared common
enetic variant.
iomarkers
esults of research on increasingly more sensitive cardiac-
pecific troponin assays continued to appear during the past
ear. A number of potential mechanisms causing an increase
n cardiac troponin have been described (12) (Table 1) and
reater understanding of the underlying pathobiology
hould help clinicians to interpret the results of low-level
levations of high sensitivity (hs) cardiac troponin assays.
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Year in NSTE-ACS November 20/27, 2012:2127–39Even brief (60 min) episodes of rapid atrial pacing in the
absence of frank infarction can cause the appearance of
troponin in coronary sinus blood (13). Therefore, clinicians
cannot rely solely on the presence of an elevated biomarker
to establish a diagnosis of acute MI (AMI). Indeed, the
specificity of some newer troponin assays may be as low as
59%, even among patients with established CHD (14).
Therefore, clinicians should integrate an understanding of
the particular troponin assay characteristics (using the 99th
percentile in normal subjects as the cut point to define
myocardial necrosis) with an interpretation in the light of
the clinical context. Because it is estimated that 60% to 70%
of individuals presenting with chest discomfort to an emer-
gency department (ED) will have measurable troponin
concentrations with higher sensitivity assays (15), clinical
acumen will become even more important to properly
evaluate, triage, and manage these patients.
Nevertheless, high-sensitivity troponin assays are ex-
tremely helpful to exclude AMI rapidly. In a prospective
ohort of 703 patients with chest pain, of whom 130 had
cute MI, none of the patients with undetectable troponin T
at baseline had AMI (16). A negative initial troponin level
not only rapidly excluded the diagnosis of AMI in 28% of
patients presenting with chest pain, but also accurately
classified these patients as at very low risk of cardiovascular
events over the next 6 months (only 1% died or had a
subsequent AMI).
Diagnostic accuracy can be improved by assessing serial
igh-sensitivity cardiac troponin T measurements. Among
,818 patients with suspected ACS, a 3-h troponin assay
ad a sensitivity of 98.2%, negative predictive value of
9.4%, and positive predictive value of 96% in the presence
f a serial change from baseline to 3 h (17). Reichlin et al.
18) studied a prospective cohort of 836 patients presenting
Pathobiological Classification of Types of PotentialMechanisms Causing Elevations of Cardiac TroponinTable 1 P thobiologic l Classific ti n of Types of PotentialMechanisms Causing Elevations of Cardiac Troponin
Type Examples/Explanation
Myocyte* necrosis Ischemia, infarction, inflammation, infiltration,
trauma, toxic/metabolic (e.g., sepsis)
Apoptosis Programmed cell death due to activation of
caspases
Normal myocyte turnover Natural low-grade annual turnover of myocytes
(unclear whether this can be detected in the
systemic circulation with current assays)
Cellular release of proteolytic
troponin degradation
products
Creation of small fragments that pass through
the intact myocyte membrane without cell
death
Increased cellular wall
permeability
Reversible injury to myocyte membranes
resulting in altered permeability (e.g., due
to stretch, ischemia)
Formation and release of
membranous blebs
Active secretion of vesicles or membrane
expression with shedding (e.g., due to
anoxia)
*Diseased skeletal muscle may also cause increases in circulating cardiac troponin T (but not
cardiac troponin I) (99). Adapted, with permission, from White (12).ith chest pain and reported that absolute changes in serialroponin levels were superior to relative changes in the
iagnosis of AMI.
An important clinical question related to biomarkers and
he definition of MI is whether the prognosis varies across
ifferent MI subtypes and specifically whether MI after
ercutaneous intervention (PCI) connotes increased cardio-
ascular risk. In an analysis of 13,608 patients with ACS
rom the TRITON-TIMI 38 trial (see Table 2 for trial
cronyms), an increased risk of cardiovascular death through
months was observed after MI overall (6.5% vs. 1.3%, p
.001) and across all subtypes, although the adjusted hazard
atios (HRs) ranged from 2.4 for peri-PCI MI to 10.8 for
tent thrombosis (19). In contrast, Damman et al. (20)
eported an increased risk of cardiovascular death at 6
onths after spontaneous MI (HR: 4.5), but not peri-PCI
I. These types of endpoint-endpoint analyses, although of
reat clinical interest, remain subject to residual confound-
ng and are extremely sensitive to the methods used to
onstruct the multivariate models and definitions appl-
ed (21).
Increased concentrations of both secretory and lipoprotein-
ssociated phospholipase A2 (sPLA2 and LpPLA2) have
een shown to identify patients with chronic coronary artery
isease who are at high risk of acute events. Among 2,587
atients with NSTE-ACS enrolled in the MIRACL trial
nd randomized to receive atorvastatin 80 mg versus placebo
or 16 weeks, sPLA2 mass independently predicted the risk
f death (22). Randomization to atorvastatin reduced the
ass and activity of both sPLA2 and LpPLA2, as well as the
increased risk of death associated with increased sPLA2
mass, suggesting a beneficial anti-inflammatory mechanism
of action by high-dose atorvastatin.
Imaging
Three randomized trials evaluated the usefulness of coro-
nary computed tomography angiography (CCTA) in pa-
tients presenting to the ED with possible ACS. Litt et al.
(23) randomized 1,370 low-to-intermediate risk patients in
a 2:1 ratio to either CCTA or traditional care. The primary
outcome of cardiac death or MI by 30 days occurred in none
of the 640 patients with negative CCTA findings, defined
as coronary stenosis 50% in major coronary vessels,
demonstrating the excellent short-term prognosis of pa-
tients with “negative” CCTA findings. Compared with the
462 patients receiving traditional care, those in the CCTA
group had a 27% absolute higher rate of discharge from the
ED, shorter average length of stay by 6.8 h, and higher rate
of detection of coronary disease (9.0% vs. 3.5%). In a trial
comparing CCTA with rest-stress myocardial perfusion
imaging, CCTA shortened the median time to diagnosis by
3 h and saved an average of $2,137, with no difference in the
incidence of major adverse events after a test with normal
results (24). Finally, the ROMICAT II trial (25) in 1,000
patients with symptoms consistent with ACS but no ischemic
electrocardiographic changes or initially elevated troponin
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November 20/27, 2012:2127–39 Year in NSTE-ACSdemonstrated that patients randomized to early CCTA
(compared with standard evaluation in the ED) reduced the
mean length of stay by 7.6 h (p  0.0002), quadrupled the
rate of patients discharged directly from the ED (47% vs.
12%, p  0.0001), and did not miss any cases of ACS (as
djudicated by an independent review), without increasing
osts. These 3 studies established that CCTA facilitates
uicker exclusion of ACS in the ED, resulting in fewer
dmissions; however, whether these benefits outweigh the
isk associated with radiation exposure or would be superior
o a strategy of judicious outpatient clinical follow-up of
hese low-risk patients remains to be determined.
Two studies of invasive imaging techniques provided
dditional insight into particularly high-risk subgroups
mong patients with ACS. Optical coherence tomography
n 26 patients with ACS and diseased saphenous vein grafts
dentified 2 characteristics, thrombi and thin fibrous caps,
hat were more strongly associated with MI compared with
A (Fig. 1) (26). A second study using virtual histology–
ntravascular ultrasound in patients with ACS reported that
he volume of the necrotic core of the plaques was the only
ndependent predictor of no-reflow after stenting (27).
These observations in patients at high risk of ACS support
the search for newer therapies that reduce, or at least
stabilize, the lipid core of coronary arterial plaques and
AcronymsTable 2 Acronyms
ACTION Acute Coronary Treatment and Intervention Outcomes Ne
ACUITY Acute Catheterization and Urgent Intervention Triage Stra
APPRAISE-2 Apixaban for Prevention of Acute Ischemic Events
ARMYDA-CIN Atorvastatin for Reduction of MYocardial Damage During
ATLAS ACS TIMI 51
ATLAS ACS The second trial of Anti-Xa Therapy to Lower cardiovascu
CLOVIS-2 Clopidogrel and Response Dose Variability Investigation S
Dal-OUTCOMES Dalcetrapib Outcomes Study
EXCELLENT Efficacy of Xience/Promus Versus Cypher to Reduce Late
GRACE Global Registry of Acute Coronary Events
GRAVITAS Gauging Responsiveness With A VerifyNow Assay—Impa
ISAR-REACT 4 Intracoronary Stenting and Antithrombotic Regimen: Rap
MIRACL Myocardial Ischemia Reduction With Aggressive Choleste
PLATO Platelet Inhibition and Patient Outcomes
PRODIGY Prolonged Dual Antiplatelet Treatment After Grading Ste
PROVE-IT TIMI 22 Pravastatin or Atorvastatin Evaluation and Infection Ther
MI FREEE Post-Myocardial Infarction Free Rx Event and Economic E
REAL-LATE Correlation of Clopidogrel Therapy Discontinuation in Rea
Thrombotic Events
RECLOSE-2 (ACS) Responsiveness to Clopidogrel and Stent-Related Events
ROMICAT Rule Out Myocardial Infarction by Computer Assisted Tom
SYNTAX Synergy Between PCI With Taxus and Cardiac Surgery
TIMI Thrombolysis in Myocardial Infarction
TRA-2P Thrombin Receptor Antagonist in Secondary Prevention o
TRACER Thrombin Receptor Antagonist for Clinical Event Reductio
TRANSLATE-ACS Treatment with ADP Receptor Inhibitors: Longitudinal As
TRITON Trial to Assess Improvement in Therapeutic Outcomes by
ZEST-LATE Evaluation of the Long-Term Safety After Zotarolimus-Elu
Lesions—Late Coronary Arterial Thrombotic Eventsthereby prevent thrombus formation after plaque rupture.Antiplatelet Therapy
This therapy remains a cornerstone in the management of
patients with ACS, and in the past year, factors that reduce
the effects of oral antiplatelet agents, the association be-
tween high platelet reactivity and clinical outcomes, new
data with novel oral antiplatelet agents, and comparisons of
different durations of dual-antiplatelet therapy (DAPT)
after stenting have been reported.
The CLOVIS-2 trial, a pharmacokinetic and pharma-
codynamic study of clopidogrel in 106 patients post-
MI, confirmed that reduced-function genetic variants in
the hepatic cytochrome P450-2C19 gene (so-called
CYP2C19*2 carriers), but not the paraoxonase-1 gene,
identified patients who generated reduced concentration of
the active metabolite of clopidogrel (28). In a study of 346
consecutive patients with NSTE-ACS who underwent
PCI, higher doses of clopidogrel (600-mg loading dose,
150-mg/day maintenance dose) overcame the low response
to clopidogrel in fewer than half the patients who were
CYP2C19*2 carriers and poor responders to clopidogrel
(29). Thus, although CYP2C19*2 status has been identified
as the most important genetic marker to date responsible for
poor response to clopidogrel as assessed by inhibition of
platelet function, simply doubling the standard dose does
plasty–Contrast-Induced Nephropathy
nts in Addition to standard therapy in Subjects with Acute Coronary Syndrome
After Stenting
hrombosis and Safety
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Year in NSTE-ACS November 20/27, 2012:2127–39translate into clinical benefit. Indeed, data from patients
with stable angina undergoing PCI suggest that a mainte-
nance dose of 225 mg clopidogrel is necessary in hetero-
zygote carriers of the CYP2C19*2 allele to achieve the same
level of platelet inhibition as that in noncarriers who receive
75 mg/day and that even a maintenance dose of 300 mg/day
is insufficient in homozygotes (30).
Two trials (31,32) investigated whether the use of more
intensive antiplatelet therapy improved clinical outcomes in
patients with high residual platelet reactivity after a standard
loading dose of clopidogrel. In the RECLOSE-2 trial (31),
patients with ACS undergoing PCI who had high residual
platelet reactivity after loading doses of 325 mg aspirin and
600 mg clopidogrel received an increased maintenance dose
of clopidogrel (150 to 300 mg/day) or were switched to
ticlopidine (500 to 1,000 mg/day). Despite this more
intensive therapy, guided by adenosine diphosphate (ADP)
testing, the patients with high residual platelet reactivity had
a 2-fold higher rate of cardiovascular events and twice the
rate of stent thrombosis than those with normal platelet
reactivity. However, this finding does not rule out the
Figure 1 Evaluation of a Culprit Lesion in an SVG of a Patient W
(A) Angiography of a saphenous vein graft (SVG) to the left anterior descending ar
shown in the magnification (asterisk). Optical coherence tomography (OCT) image
underneath (C) (asterisk). (C, D) Arrows point to a signal-rich layer, underneath w
rich layer probably represents friable tissue “detached” from the SVG wall. In all O
from Davlouros et al. (26).potential benefit of even more intensive antiplatelet therapy. (In fact, an analysis from the GRAVITAS trial showed that
patients who achieved the even lower threshold of 208
2Y12 reaction units (instead of the previous standard of
230) 12 to 24 h post-PCI did experience a lower risk of
ubsequent cardiovascular events (32). Thus, controversy
ersists on the utility of platelet function testing and
enotyping to improve outcomes, with proponents on both
ides of the debate (33,34). Although genetic testing and
ssessment of platelet function identify patients at higher
isk in population studies, it has not been established
hether such testing will be clinically useful to guide
herapy in individual patients.
In previous Year in Cardiology reviews (35,36), we
escribed the conflicting findings from several studies re-
arding the presence of a drug–drug interaction between
roton pump inhibitors (PPIs) and clopidogrel related to
ompetition for metabolism by the cytochrome P450 3A4
CYP3A4) enzyme. Previous observational studies reported
orse outcomes in patients taking both a PPI and clopi-
ogrel, and it was hypothesized that this was due to a
ecreased generation of the active clopidogrel metabolite
Non–ST-Segment Elevation Myocardial Infarction by OCT
ith severe narrowing and thrombus (white box). Plaque ulceration with a flap is
e site of the lesion, red thrombus (B) (arrow), intimal rupture with a large cavity
signal-free layer is evident, separating the former from the SVG wall. The signal-
mes, fibrofatty composition of the intima is evident. Reprinted, with permission,ith
tery w
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November 20/27, 2012:2127–39 Year in NSTE-ACSintensive antiplatelet effect. However, analyses by Goodman
et al. (37) from the PLATO trial, which compared clopi-
dogrel with ticagrelor (which does not depend on the
cytochrome P450 enzyme for action), in patients with ACS
concluded that the presence of residual confounding was the
major explanation for the higher event rates in patients who
received a PPI with clopidogrel. In this analysis, patients in
the PLATO trial who were treated with a PPI were at
higher risk of ischemic events than patients who were not
treated with a PPI, regardless of whether the patients had
been randomized to clopidogrel or ticagrelor. In addition,
the magnitude of the incremental increase in risk of ische-
mic events associated with treatment with a PPI was
similar for patients randomized to clopidogrel compared
with those randomized to ticagrelor. Furthermore, use of
non-PPI gastroprotective agents was associated with similar
degree of increased ischemic risk in the ticagrelor and
clopidogrel groups compared with patients who did not use
a gastroprotective agent. Therefore, it appears that PPIs (or
non-PPI gastroprotective agents) were used in patients at
higher risk of ischemic events, regardless of which antiplatelet
agent was administered.
Another alternative to achieve high-intensity platelet
inhibition in patients with the CYP2C19*2 genotype is the
third-generation thienopyridine prasugrel. After a loading
dose of prasugrel 60 mg was given to 23 patients with at
least 1 CYP2C19*2 allele, all 23 achieved the target level of
platelet inhibition (P2Y12 reactivity units 234) using a
point-of-care device (38). However, using an alternative
method to assess platelet reactivity (vasodilator-stimulated
phosphoprotein [VASP] index), a loading dose of prasugrel
60 mg did not achieve the optimal level of antiplatelet effect
in 25% of patients with ACS undergoing PCI (39). A third
Figure 2 ASA Dose and Outcomes With Clopidogrel Versus Tic
Kaplan-Meier estimated event rates for the primary efficacy outcome (composite o
(ticagrelor vs. clopidogrel) and open-label median maintenance aspirin (ASA) dose
confidence interval; HR  hazard ratio. Adapted, with permission, from Mahaffey eharmacokinetics study in patients on maintenance prasu-
rel therapy (10 mg/day) compared 3 different strategies
60-mg reload, 30-mg reload, and continuation of 10 mg
rasugrel) (40); the 60-mg reload strategy achieved greater
latelet inhibition than the continuation of 10 mg at 1 and
h, whereas 30 mg achieved intermediate results. Thus,
rasugrel 60 mg (as a load or reload) is effective in achieving
igh-level platelet inhibition in a large majority of patients
including carriers of the CYP2C19*2 allele). Last, switch-
ng stable patients with high on-treatment platelet reactivity
n clopidogrel to prasugrel permitted 94% of patients to
chieve the target level of platelet inhibition after 3 months
41). An important goal for future studies and guidelines is
o establish a reliable, cost-effective, and widely available
ethod to rapidly measure the inhibitory effects of anti-
latelet agents.
Ticagrelor is a third potential option for long-term,
otent, oral antiplatelet therapy in patients with NSTE-
CS. New information becoming available during the past
ear examining geographic variation in outcomes in the
LATO trial suggested strongly that differences in the
aintenance dose of aspirin (most commonly 325 mg in
he United States vs. 100 mg elsewhere) can explain the
ess favorable results seen in patients enrolled in the United
tates (Fig. 2), although residual confounding or the play of
hance cannot be excluded (42). Based on these analyses,
he U.S. Food and Drug Administration recommends a low
aintenance dose (75 to 100 mg) of aspirin in combination
ith ticagrelor. Another subgroup analysis from the
LATO trial concluded that the efficacy and safety results
n patients with a history of stroke or transient ischemic
ttack were similar to those of the overall trial results (43).
his is in contrast with the less favorable results observed
or in PLATO
ovascular death, myocardial infarction, stroke) by blinded, randomized treatment
istered at the investigator’s discretion from randomization through 30 days. CI 
2).agrel
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Year in NSTE-ACS November 20/27, 2012:2127–39with prasugrel in patients with previous stroke or transient
ischemic attack (44). However, given the relatively small
number of ACS patients with a history of cerebrovascular
disease, it is prudent now not to use any of the new potent
new oral antithrombotic agents (i.e., prasugrel or ticagrelor
or the addition of an Xa inhibitor to antiplatelet therapy
see below]) to patients with ACS and a history of stroke
r transient ischemic attack (45).
Three papers compared longer durations (12 to 24
onths) with shorter durations (6 to 12 months) of DAPT
n patients after coronary stenting, most of whom had ACS
46–48). No additional benefit with DAPT treatment
eyond 12 months was observed, and the largest study (48)
emonstrated a 2-fold increase in bleeding, with DAPT for
4 months versus 6 months. Despite their limitations
open-label, low statistical power, use of 3 different types of
tents), none of the trials provide evidence of a reduction in
he clinically important composite of death or MI with
rolonged DAPT (Fig. 3). However, these trials were not
arge enough to offer conclusive evidence. A large (20,000)
atient trial is well under way to provide such evidence (49).
The protease-activated receptor 1 antagonists, which
block the platelet thrombin receptors, represent a new class
of antiplatelet agents. Vorapaxar (40-mg load followed by
2.5 mg/day) when added to conventional therapy was
compared with placebo in 12,944 patients with NSTE-
ACS in the TRACER trial (50). The primary composite
endpoint of cardiovascular death, MI, stroke, recurrent
ischemia requiring rehospitalization, or urgent coronary
revascularization occurred in 18.5% of patients randomized
to vorapaxar compared with 19.9% placebo (p  0.07).
Although vorapaxar reduced the major secondary endpoint
Figure 3 Prolonged DAPT After Percutaneous Coronary Interve
The rates of death or myocardial infarction (MI) were similar for shorter versus lon
(47), PRODIGY trial (48), and EXCELLENT trial (46). ACS  acute coronary syndrom
PES  paclitaxel-eluting stent(s); SES  sirolimus-eluting stent(s); ZES  zotarolimof cardiovascular death, MI, or stroke significantly (14.7%
vs. 16.4%, p  0.02), this was counterbalanced by a 2%
increase in moderate or severe bleeding, including intracra-
nial bleeding, particularly in patients with low body weight
or those who also received thienopyridine and aspirin. Of
note, when started 2 to 52 weeks post-MI, vorapaxar 2.5
mg/day (with no loading dose) significantly reduced a
variety of cardiovascular events compared with placebo in
the TRA-2P trial, although bleeding was increased (51).
Intravenous antiplatelet therapy continues to fill an ever
smaller role in patients with ACS undergoing PCI. A
meta-analysis of 12 trials involving 46,374 patients with
NSTE-ACS demonstrated that upstream use of small-
molecule glycoprotein IIb/IIIa inhibitors provided a modest
11% reduction in death or MI at 30 days but no difference
in mortality and a 23% increase in major bleeding (52).
Some of the excess bleeding risk could be mitigated if
patients with impaired renal function (creatinine clearance
50 ml/min) received a reduced dose, as recommended in
the prescribing information.
In the ISAR-REACT 4 trial, the combination of abcix-
imab and heparin, compared with bivalirudin in a trial of
1,721 patients with NSTE-ACS, failed to reduce the major
adverse events (death, large MI, urgent target-vessel revas-
cularization, major bleeding) or ischemic events alone
through 30 days. Major bleeding, however was increased in
the abciximab/heparin group. In light of the consistent
repeated findings of small to no reduction in ischemic
complications with more bleeding, as mentioned above (52)
and in previous Years in Cardiology reviews (35,53), intra-
venous glycoprotein IIb/IIIa inhibitors appear to be most
useful in ACS patients at high risk of thrombotic compli-
al-antiplatelet therapy (DAPT) in the REAL-LATE and ZEST-LATE combined analysis
S  everolimus eluting stent(s); HR  hazard ratio; MI  myocardial infarction;
uting stent(s).ntion
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November 20/27, 2012:2127–39 Year in NSTE-ACScations during PCI who are not receiving bivalirudin or as
provisional therapy in patients receiving bivalirudin (54). A
arge prospective, observational longitudinal registry
TRANSLATE-ACS) is currently tracking 17,000 patients
ith MI in 350 U.S. hospitals and should provide a
omprehensive, systematic picture of current treatment
atterns with antithrombotic agents and outcomes in rou-
ine clinical practice (55).
ral Anticoagulants
wo phase III trials with novel oral factor Xa inhibitors in
atients with ACS reported results during the past year. In
he APPRAISE-2 trial, 7,392 patients with recent ACS
60% with NSTE-ACS) and at least 2 additional risk
actors were randomized to receive apixaban 5 mg twice
aily or placebo in addition to standard antiplatelet therapy
81% on DAPT). Enrollment was prematurely terminated
ue to excess major bleeding in the absence of a reduction
ecurrent ischemic events with apixaban.
In contrast, in the ATLAS ACS TIMI 51 trial of 15,526
atients with ACS (50% with NSTE-ACS, 93% on
APT) followed for a mean of 13 months and up to 31
onths, both doses of rivaroxaban (2.5 and 5 mg twice
aily) studied significantly reduced the primary ischemic
omposite of cardiovascular death, MI, or stroke. Rivaroxa-
an also reduced stent thrombosis by 31% (p  0.02) (56).
urthermore, rivaroxaban 2.5 mg twice daily significantly
educed cardiovascular death by 34% (Fig. 4) and all-cause
ortality by 32%. Rivaroxaban increased the rates of non–
oronary artery bypass graft major bleeding (2.1% vs. 0.6%,
 0.001) and intracranial bleeding (0.6% vs. 0.2%, p 
0.009), although there was no difference in fatal bleeding
Figure 4 Death From Cardiovascular Causes,
Rivaroxaban 2.5 mg Twice Daily
The cumulative incidence of cardiovascular death in patients after non–ST-
segment elevation acute coronary syndromes who received aspirin and a thien-
opyridine and were randomized to placebo (n  5,114) vs rivaroxaban 2.5 mg
twice daily (n  5,113). Abbreviations as in Figure 2. Adapted, with permis-
sion, from Mega et al. (56).(0.3% vs. 0.2%), and the 2.5-mg twice daily dose wasassociated with a significantly lower rate of fatal bleeding
(0.1%) than the 5-mg twice daily dose (0.4%, p  0.04).
It is possible that the differences in outcomes between the
APPRAISE-2 and ATLAS-2 TIMI 51 trials can be ac-
counted for by the higher dose of the Xa inhibitor and the
greater number of patients with a history of stroke or
transient ischemic attack in APPRAISE-2.
Bleeding
A comprehensive paper by the Working Group on Throm-
bosis of the ESC (57) summarized the current epidemiology
and adverse effects (Fig. 5) of bleeding in ACS and PCI,
compared various definitions (including the recently de-
signed consensus classification from the Bleeding Academic
Research Consortium [Table 3]), and described strategies to
reduce the risk of bleeding and to manage hemorrhage when
it occurs. For the practicing clinician, practical suggestions
to minimize bleeding include: 1) avoidance of overdosing of
antithrombotics, particularly in patients with chronic kidney
disease (CKD) (58); 2) use of the shortest possible of
duration of administration of antithrombotics; 3) preference
for drugs (such as bivalirudin) that cause less bleeding while
maintaining anti-ischemic efficacy; 4) minimization of con-
comitant therapies (such as nonsteroidal anti-inflammatory
drugs) that increase the risk of gastrointestinal bleeding;
5) use of gastroprotective drugs in patients at high risk of
gastrointestinal bleeding; and 6) prevention of access site
bleeding by the use of radial access, smaller sheath sizes,
arterial closure devices, and timely removal of sheaths. Key
recommendations for the management of bleeding include
interruption and/or neutralization of antithrombotic ther-
Figure 5 Why Bleeding May Cause Mortality
Schematic diagram of hypothetical mechanisms that may explain the associa-
tion between bleeding and mortality. Adapted, with permission, from Steg
et al. (57).
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achieved by specific interventions), withholding of transfu-
sions in hemodynamically stable patients with a hemoglobin
level8 g/dl and no overt bleeding, and the continuation of
antithrombotic therapy in the presence of minor bleeding.
Two papers reported a graded increase in mortality
through 1 year with increasing severity of bleeding in
patients (some of whom had previous ACS) undergoing
PCI. One analysis used (and validated) the Bleeding Aca-
demic Research Consortium definition (59) (Table 3), and
the second used the Thrombolysis In Myocardial Infarction
major bleeding definition to develop a bleeding risk score
(60). Although it appears quite clear that patients who bleed
have a higher rate of mortality in the short and long term
compared with patients who do not bleed, establishing a
Bleeding Academic Research ConsortiumDefinition for BleedingTable 3 Bl ding Academic Research ConsortiumDefinition for Bleeding
Type 0 No bleeding
Type 1 Bleeding that is not actionable and does not cause the patient to seek
unscheduled performance of studies, hospitalization, or treatment
by a health care professional
Type 2 Any overt, actionable sign of hemorrhage (e.g., more bleeding than
would be expected in a clinical circumstance, including bleeding
found by imaging alone) that does not fit the criteria for type 3, 4,
or 5, but does meet at least 1 of the following criteria: 1) requiring
nonsurgical, medical intervention by a health care professional; 2)
leading to hospitalization or increased level of care; 3) prompting
evaluation
Type 3
Type 3a Overt bleeding that is associated with either or both of the following:
hemoglobin decrease of 3 to 5*g/dl (provided hemoglobin
decrease is related to bleed); a transfusion
Type 3b Overt bleeding that is associated with at least 1 of the following:
hemoglobin decrease 5*g/dl (provided hemoglobin decrease is
related to bleed); cardiac tamponade; requires surgical intervention
for control of bleeding (excluding dental/nasal/skin/hemorrhoid);
requires intravenous vasoactive drugs
Type 3c Bleeding that satisfies at least 1 of the following: intracranial
hemorrhage (does not include microbleeds or hemorrhagic
transformation, does include intraspinal); subcategories; confirmed
by autopsy or imaging or lumbar puncture; intraocular bleed
compromising vision
Type 4 CABG-related bleeding: bleeding during or after coronary artery bypass
graft that meets at least 1 of the following:
Perioperative intracranial bleeding within 48 h
Reoperation after closure of sternotomy for the purpose of controlling
bleeding
Transfusion of 5 U of whole blood or packed red blood cells within a
48 period†
Chest tube output 2 l within a 24-h period
If a CABG-related bleed is not adjudicated as at least a type 3 severity
event, it will be classified as not a bleeding event
Type 5 Fatal bleeding
Type 5a Probable fatal bleeding: no autopsy or imaging confirmation, but
clinically suspicious
Type 5b Definite fatal bleeding: overt bleeding or autopsy or imaging
confirmation
Note: Platelet transfusions should be recorded and reported, but are not included in these
definitions until further information is obtained about the relationship to outcomes. *Corrected for
transfusion (1 U of packed red blood cells or 1 U of whole blood  1 g/dl Hgb). †Only allogeneic
transfusions are considered transfusions for Bleeding Academic Research Consortium type 4
bleeding. Cell saver products will not be counted.causal relationship remains challenging due to the persis- 1tence of confounding because bleeding occurs more fre-
quently in patients who are at higher risk of adverse
outcomes (61). The complexity of the relationship between
bleeding and clinical outcome is emphasized by the finding
that 2 new antithrombotic therapies, ticagrelor (62) and very
low dose rivaroxaban (56), which reduced mortality, could be
ssociated with higher rates of non–coronary artery bypass
raft bleeding. Singh et al. (63) introduced the concept of
patient frailty” as a potential unmeasured confounder that
ould serve as an important missing link between clinical
vents (e.g., bleeding, stent thrombosis) and mortality (64).
Due to the increased potential for bleeding among
atients who are receiving long-term treatment with vita-
in K antagonists in whom ACS develops, new research
as focused on this particularly high-risk subgroup. Current
uidelines (based mostly on expert consensus) recommend
hat in patients who are treated with vitamin K antagonists
n whom ACS develops, parenteral anticoagulation should
e held until the international normalized ratio (INR) is
ubtherapeutic, but that dual antiplatelet therapy should be
dministered at presentation. In a retrospective analysis
rom the National Cardiovascular Data Registry, Subherwal
t al. (65) reviewed the practice patterns and outcomes in
atients with NSTEMI receiving warfarin, often with
ackground antiplatelet therapy. As anticipated, higher
dmission INRs were associated with higher rates of bleed-
ng. However, in contrast to current guidelines, nearly half
f the patients with INRs 2.0 did not have parenteral
nticoagulation withheld in the first 24 h, whereas early
lopidogrel was given to only one third of patients. The
ivergence between the guideline recommendations and
linical practice provides an opportunity for future random-
zed studies to more clearly establish the optimal antithrom-
otic strategy in these patients.
nvasive Management
s this topic was covered in another recently published Year
n Cardiology review (66) and detailed U.S. guidelines were
eleased in December 2011 (54), we focus here on new
nformation related to 2 aspects of care in patients with
STE-ACS undergoing PCI: management of high-risk
atients and the safety and efficacy of third-generation
tents.
igh-risk patients. Two analyses (67,68) compared out-
omes with an invasive strategy in women with NSTE-ACS
eached conflicting conclusions. Alfredsson et al. (67) followed
6,455 patients (32% women) from the SWEDEHEART
egistry for 1 year. After multivariate adjustment, there was
substantial benefit of an early invasive strategy in women
relative risk for death: 0.46; relative risk for death/MI:
.57), which was similar to that observed in men, with no
vidence of an interaction with sex. In contrast, a meta-
nalysis of 5 trials showed no benefit of an invasive strategy
n women with regard to death or MI (odds ratio [OR]:
.18) or mortality (OR: 1.51) (68). These findings were
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in men (OR for death or MI: 0.78; OR for mortality: 0.70)
with interaction p values of 0.010 and 0.012, respectively. A
large adequately powered randomized trial in women would
be helpful to clarify these contradictory results.
Patients with NSTE-ACS and CKD represent a chal-
lenging clinical problem due to the higher risk of both
ischemic events and complications (bleeding, renal failure)
when undergoing PCI (58). An analysis from the ACTION
registry of 12,045 patients with NSTEMI and CKD who
underwent PCI revealed that these patients had more
comorbidities (previous MI, heart failure, 3-vessel coronary
artery disease) and were less likely to receive guideline-
recommended therapies than patients with normal renal
function (69). An observational analysis of 3,442 patients
with NSTEMI and CKD from a South Korean registry
showed lower mortality with an invasive strategy compared
with conservative management in patients with mild or
moderate CKD, but similar outcomes in patients with
creatinine clearance 30 ml/min (70). An intervention that
may reduce morbidity and mortality in patients with CKD
undergoing coronary angiography is short-term administra-
tion of high-dose atorvastatin to prevent contrast-induced
nephropathy. In the ARMYDA-CIN trial, statin-naive
patients with ACS undergoing PCI who received 80 mg
atorvastatin 12 h before intervention with another 40 mg
pre-procedure had a lower rate of contrast-induced ne-
phropathy (defined as an absolute increase in serum creat-
inine of 0.5 mg/dl or 25% relative increase from the
baseline) compared with placebo (5.0% vs. 13.2%, p 
0.046) (71).
Two publications assessed risk scores to predict outcomes
at 1 year (72) and in patients 65 years of age or older out to
3 years (73) after admission for ACS managed with PCI. In
an analysis of 2,627 patients with NSTE-ACS enrolled in
the angiographic substudy of the ACUITY trial (72), the
SYNTAX score (74), an angiographic scoring system that
ranks the complexity of coronary anatomy, was found to be
an independent predictor of 1-year all-cause death, cardiac
death, MI, and target vessel revascularization. Weintraub et
al. (73) showed in 343,466 patients older than 65 years of
age with and without STEMI who underwent PCI and
were enrolled in the CathPCI Registry that a model
including 24 characteristics related to demographics, co-
morbidity, previous disease, and indices of disease severity
and acuity accurately predicted mortality at 3 years. These 2
sophisticated prediction tools (i.e., the SYNTAX score and
the CathPCI model) should prove to be helpful in the
assessment of the individual risk–benefit of PCI. Last, the
presence of incomplete angiographic coronary revasculariza-
tion was found to be a novel marker of increased risk in
patients with ACS undergoing PCI in an analysis of from
the ACUITY trial (75) that may need to be incorporated in
future scores.
Third-generation drug-eluting stents. Data from indi-
vidual randomized clinical trials (76,77), patient-levelpooled analysis (78), and a network meta-analysis (79)
evaluating the everolimus-eluting stent demonstrated
consistent benefits over earlier generation drug-eluting
stents (sirolimus, paclitaxel) and bare-metal stents. The
everolimus-eluting stent was associated with reductions in
major adverse cardiac events, target vessel revascularization,
and stent thrombosis (early, i.e., within the first 30 days, as
well as very late, i.e., beyond 1 year). With continued
improvements in outcomes (particularly reductions in non-
acute stent thrombosis) with newer generations of drug-
eluting stents, the need for prolonged potent oral anti-
thrombotic therapy may lessen.
Lipid-Modifying Therapies
The past year brought more good news for statin therapy, a
big disappointment for the cholesteryl ester transfer protein
inhibitor dalcetrapib, and hope for drugs with different
lipid-altering mechanisms. Truong et al. (80) reported
similar benefit with atorvastatin 80 mg over pravastatin 40
mg post-ACS in women versus men in the PROVE-IT
TIMI 22 trial. In addition, no differences between the sexes
were seen in the safety profile of high-dose atorvastatin,
including evaluation of biochemical elevations of liver and
muscle enzymes or clinical myopathy. These findings are
consistent with a meta-analysis of 18 randomized primary
and secondary prevention clinical trials involving 40,275
women that demonstrated similar significant decreases in
cardiovascular events and in all-cause mortality in women
and in men, thus supporting the use of statin therapy in
appropriate patients regardless of sex (81).
Two other groups of patients who appear to benefit from
early aggressive statin use include those after acute MI with
extremely low low-density lipoprotein (LDL) cholesterol
concentration (i.e., 70 mg/dl) and those undergoing PCI.
Lee et al. (82) analyzed 1,054 patients with acute MI and
baseline LDL 70 mg/dl from the Korean Acute MI
Registry and found that early statin therapy reduced the rate
of major adverse cardiac events, cardiac death, and coronary
revascularizations at 1 year. In a patient-level meta-analysis
of 13 randomized trials involving 3,341 patients undergoing
PCI (39% of whom had ACS), pretreatment with high-
dose statin reduced the risk of peri-PCI MI by 44% and the
rate of major adverse cardiac events by 44% at 30 days (both
p  0.001) (83). Unfortunately, approximately 30% of
patients did not undergo lipid testing during hospitaliza-
tion after ACS in an analysis from the GRACE registry
in Canadian hospitals (84), and the lack of such testing is
one of the strongest predictors of discharge without statin
therapy.
Perhaps the biggest surprise of the year in this field was
the announcement in May 2012 of the premature termina-
tion of the phase III Dal-OUTCOMES trial investigating
the cholesteryl ester transfer protein inhibitor dalcetrapib in
15,600 patients 4 to 12 weeks post-ACS. A press release
from the sponsor (85) stated that the independent data and
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second interim analysis, recommended stopping the trial
due to a lack of clinically meaningful efficacy with dalce-
trapib. No safety signals relating to the Dal-OUTCOMES
trial were reported.
Two other novel therapies that are being investigated in
patients post-ACS target very different pathways. Darap-
ladib is a novel, selective, reversible, orally active inhibitor of
lipoprotein-associated phospholipase A2 activity that may
confer clinical benefit by reducing and stabilizing the
necrotic core of lipid-rich atherosclerotic plaques is being
evaluated in 13,000 patients post-ACS (86). Two mono-
clonal antibodies that inhibit proprotein convertase subtili-
sin/kexin type 9, thus interfering with its role in facilitating
the degradation of hepatic LDL receptors, thereby lowering
LDL cholesterol concentrations, have completed phase II
studies and phase III trials are imminent (87).
Quality of Care
Dissemination of multiple and frequently updated guide-
lines (such those recently published for secondary preven-
tion [88]), career-long medical education, and quality im-
provement efforts (89) have increased the delivery of
evidence-based treatments to physicians (90). However, the
application of well-established therapies is not uniform. For
example, although statin use post-ACS has now become a
widely accepted standard of care, a retrospective chart
review of randomly selected patients with ACS admitted to
a university hospital in Canada reported that only 52% of
those eligible actually received high-intensity statin before
hospital discharge, and of these, only 68% continued on this
therapy (91). In addition, selected groups including women
(92), patients at higher risk of mortality (93), and those in
low-income countries (94) or remote areas (95) are even less
likely to receive proven therapies.
A number of innovative solutions have been proposed to
improve the quality of care, but few have been adequately
tested. In Brazil, a multifaceted educational intervention
that included reminders, checklists, case management, and
educational materials provided in print and on the Internet,
augmented by on-site training visits and off-site workshops
using simulation-based learning techniques achieved a
higher rates of use of proven acute (68% vs. 50%, p  0.01)
nd discharge (51% vs. 32%, p  0.03) therapies in patients
ith ACS compared with control (96). Two interventions
hat provided financial incentive, one to providers and the
ther to patients, met with mixed results. A study compar-
ng outcomes in patients admitted to hospitals with pay-
or-performance programs with control hospitals reported
o difference in 30-day mortality rates post-MI (97). In the
I FREEE trial (98), rates of adherence to standard drugs
ost-MI were low, ranging from 36% to 49%. Elimination
f copayments modestly (by 4% to 6% absolute, p  0.001
or all comparisons) increased adherence to drug therapies,
ut did not reduce the primary endpoint of first majorascular event or revascularization. However, there were
tatistically significant reductions in the rates of total major
ascular events or revascularization (HR: 0.89, p  0.03)
nd first major vascular event (HR: 0.86, p  0.03).
limination of copayments decreased overall health care
osts (Table 4) (98), a finding that was largely driven by a
eduction in total events, in particular, stroke and myocar-
ial ischemia/infarction. These findings underscore the
mportance of analyzing the total benefits and costs to the
ealth care system because focusing only on drug costs may
ield a misleading conclusion regarding the global cost–
enefit of a particular therapy, strategy, or health care policy.
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